Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Vertex, Inc. (NASDAQ: VERX) posted double-digit revenue growth in the third quarter of 2025 and announced its first-ever ...

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - Second pivotal development ...

As the U.S. stock market navigates a mixed landscape with tech shares rebounding and the Dow Jones Industrial Average experiencing declines, investors are closely watching for opportunities amid ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

- Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein ...